Industry Research Reports

Home > Reports > Pharma & Healthcare > Broluzumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Broluzumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Pharma & Healthcare

Published Date: 2025-01-16

Pages: 189 Pages

Report ld: 3462144

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Broluzumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Broluzumab Biosimilars, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Broluzumab Biosimilars by region & country, by Type, and by Application.

The Broluzumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Broluzumab Biosimilars.

MARKET SEGMENTATION

By Company

Novartis
Genentech
Roche
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Beovu
Vsiqq
Others

Segment by Application

ARMD
Kaposi Sarcoma
Glioblastoma

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Broluzumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Broluzumab Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Broluzumab Biosimilars in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Broluzumab Biosimilars Product Introduction

1.2 Global Broluzumab Biosimilars Market Size Forecast

1.2.1 Global Broluzumab Biosimilars Sales Value (2020-2031)

1.2.2 Global Broluzumab Biosimilars Sales Volume (2020-2031)

1.2.3 Global Broluzumab Biosimilars Sales Price (2020-2031)

1.3 Broluzumab Biosimilars Market Trends & Drivers

1.3.1 Broluzumab Biosimilars Industry Trends

1.3.2 Broluzumab Biosimilars Market Drivers & Opportunity

1.3.3 Broluzumab Biosimilars Market Challenges

1.3.4 Broluzumab Biosimilars Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Broluzumab Biosimilars Players Revenue Ranking (2024)

2.2 Global Broluzumab Biosimilars Revenue by Company (2020-2025)

2.3 Global Broluzumab Biosimilars Players Sales Volume Ranking (2024)

2.4 Global Broluzumab Biosimilars Sales Volume by Company Players (2020-2025)

2.5 Global Broluzumab Biosimilars Average Price by Company (2020-2025)

2.6 Key Manufacturers Broluzumab Biosimilars Manufacturing Base and Headquarters

2.7 Key Manufacturers Broluzumab Biosimilars Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Broluzumab Biosimilars

2.9 Broluzumab Biosimilars Market Competitive Analysis

2.9.1 Broluzumab Biosimilars Market Concentration Rate (2020-2025)

2.9.2 Global 5 and 10 Largest Manufacturers by Broluzumab Biosimilars Revenue in 2024

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Broluzumab Biosimilars as of 2024)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Beovu

3.1.2 Vsiqq

3.1.3 Others

3.2 Global Broluzumab Biosimilars Sales Value by Type

3.2.1 Global Broluzumab Biosimilars Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Broluzumab Biosimilars Sales Value, by Type (2020-2031)

3.2.3 Global Broluzumab Biosimilars Sales Value, by Type (%) (2020-2031)

3.3 Global Broluzumab Biosimilars Sales Volume by Type

3.3.1 Global Broluzumab Biosimilars Sales Volume by Type (2020 VS 2024 VS 2031)

3.3.2 Global Broluzumab Biosimilars Sales Volume, by Type (2020-2031)

3.3.3 Global Broluzumab Biosimilars Sales Volume, by Type (%) (2020-2031)

3.4 Global Broluzumab Biosimilars Average Price by Type (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 ARMD

4.1.2 Kaposi Sarcoma

4.1.3 Glioblastoma

4.2 Global Broluzumab Biosimilars Sales Value by Application

4.2.1 Global Broluzumab Biosimilars Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Broluzumab Biosimilars Sales Value, by Application (2020-2031)

4.2.3 Global Broluzumab Biosimilars Sales Value, by Application (%) (2020-2031)

4.3 Global Broluzumab Biosimilars Sales Volume by Application

4.3.1 Global Broluzumab Biosimilars Sales Volume by Application (2020 VS 2024 VS 2031)

4.3.2 Global Broluzumab Biosimilars Sales Volume, by Application (2020-2031)

4.3.3 Global Broluzumab Biosimilars Sales Volume, by Application (%) (2020-2031)

4.4 Global Broluzumab Biosimilars Average Price by Application (2020-2031)

5 Segmentation by Region

5.1 Global Broluzumab Biosimilars Sales Value by Region

5.1.1 Global Broluzumab Biosimilars Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Broluzumab Biosimilars Sales Value by Region (2020-2025)

5.1.3 Global Broluzumab Biosimilars Sales Value by Region (2026-2031)

5.1.4 Global Broluzumab Biosimilars Sales Value by Region (%), (2020-2031)

5.2 Global Broluzumab Biosimilars Sales Volume by Region

5.2.1 Global Broluzumab Biosimilars Sales Volume by Region: 2020 VS 2024 VS 2031

5.2.2 Global Broluzumab Biosimilars Sales Volume by Region (2020-2025)

5.2.3 Global Broluzumab Biosimilars Sales Volume by Region (2026-2031)

5.2.4 Global Broluzumab Biosimilars Sales Volume by Region (%), (2020-2031)

5.3 Global Broluzumab Biosimilars Average Price by Region (2020-2031)

5.4 North America

5.4.1 North America Broluzumab Biosimilars Sales Value, 2020-2031

5.4.2 North America Broluzumab Biosimilars Sales Value by Country (%), 2024 VS 2031

5.5 Europe

5.5.1 Europe Broluzumab Biosimilars Sales Value, 2020-2031

5.5.2 Europe Broluzumab Biosimilars Sales Value by Country (%), 2024 VS 2031

5.6 Asia Pacific

5.6.1 Asia Pacific Broluzumab Biosimilars Sales Value, 2020-2031

5.6.2 Asia Pacific Broluzumab Biosimilars Sales Value by Region (%), 2024 VS 2031

5.7 South America

5.7.1 South America Broluzumab Biosimilars Sales Value, 2020-2031

5.7.2 South America Broluzumab Biosimilars Sales Value by Country (%), 2024 VS 2031

5.8 Middle East & Africa

5.8.1 Middle East & Africa Broluzumab Biosimilars Sales Value, 2020-2031

5.8.2 Middle East & Africa Broluzumab Biosimilars Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Broluzumab Biosimilars Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Broluzumab Biosimilars Sales Value

6.2.1 Key Countries/Regions Broluzumab Biosimilars Sales Value, 2020-2031

6.2.2 Key Countries/Regions Broluzumab Biosimilars Sales Volume, 2020-2031

6.3 United States

6.3.1 United States Broluzumab Biosimilars Sales Value, 2020-2031

6.3.2 United States Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Broluzumab Biosimilars Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Broluzumab Biosimilars Sales Value, 2020-2031

6.4.2 Europe Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Broluzumab Biosimilars Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Broluzumab Biosimilars Sales Value, 2020-2031

6.5.2 China Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

6.5.3 China Broluzumab Biosimilars Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Broluzumab Biosimilars Sales Value, 2020-2031

6.6.2 Japan Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Broluzumab Biosimilars Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Broluzumab Biosimilars Sales Value, 2020-2031

6.7.2 South Korea Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Broluzumab Biosimilars Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Broluzumab Biosimilars Sales Value, 2020-2031

6.8.2 Southeast Asia Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Broluzumab Biosimilars Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Broluzumab Biosimilars Sales Value, 2020-2031

6.9.2 India Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

6.9.3 India Broluzumab Biosimilars Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Novartis

7.1.1 Novartis Company Information

7.1.2 Novartis Introduction and Business Overview

7.1.3 Novartis Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.1.4 Novartis Broluzumab Biosimilars Product Offerings

7.1.5 Novartis Recent Development

7.2 Genentech

7.2.1 Genentech Company Information

7.2.2 Genentech Introduction and Business Overview

7.2.3 Genentech Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.2.4 Genentech Broluzumab Biosimilars Product Offerings

7.2.5 Genentech Recent Development

7.3 Roche

7.3.1 Roche Company Information

7.3.2 Roche Introduction and Business Overview

7.3.3 Roche Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.3.4 Roche Broluzumab Biosimilars Product Offerings

7.3.5 Roche Recent Development

7.4 Pfizer

7.4.1 Pfizer Company Information

7.4.2 Pfizer Introduction and Business Overview

7.4.3 Pfizer Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.4.4 Pfizer Broluzumab Biosimilars Product Offerings

7.4.5 Pfizer Recent Development

7.5 Sartorius

7.5.1 Sartorius Company Information

7.5.2 Sartorius Introduction and Business Overview

7.5.3 Sartorius Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.5.4 Sartorius Broluzumab Biosimilars Product Offerings

7.5.5 Sartorius Recent Development

7.6 Eli Lilly

7.6.1 Eli Lilly Company Information

7.6.2 Eli Lilly Introduction and Business Overview

7.6.3 Eli Lilly Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.6.4 Eli Lilly Broluzumab Biosimilars Product Offerings

7.6.5 Eli Lilly Recent Development

7.7 Bayer

7.7.1 Bayer Company Information

7.7.2 Bayer Introduction and Business Overview

7.7.3 Bayer Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.7.4 Bayer Broluzumab Biosimilars Product Offerings

7.7.5 Bayer Recent Development

7.8 Amgen

7.8.1 Amgen Company Information

7.8.2 Amgen Introduction and Business Overview

7.8.3 Amgen Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.8.4 Amgen Broluzumab Biosimilars Product Offerings

7.8.5 Amgen Recent Development

7.9 PlantForm

7.9.1 PlantForm Company Information

7.9.2 PlantForm Introduction and Business Overview

7.9.3 PlantForm Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.9.4 PlantForm Broluzumab Biosimilars Product Offerings

7.9.5 PlantForm Recent Development

7.10 PharmaPraxis

7.10.1 PharmaPraxis Company Information

7.10.2 PharmaPraxis Introduction and Business Overview

7.10.3 PharmaPraxis Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.10.4 PharmaPraxis Broluzumab Biosimilars Product Offerings

7.10.5 PharmaPraxis Recent Development

7.11 Samsung Bioepis

7.11.1 Samsung Bioepis Company Information

7.11.2 Samsung Bioepis Introduction and Business Overview

7.11.3 Samsung Bioepis Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.11.4 Samsung Bioepis Broluzumab Biosimilars Product Offerings

7.11.5 Samsung Bioepis Recent Development

7.12 Centus

7.12.1 Centus Company Information

7.12.2 Centus Introduction and Business Overview

7.12.3 Centus Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.12.4 Centus Broluzumab Biosimilars Product Offerings

7.12.5 Centus Recent Development

7.13 Cadila Pharmaceuticals

7.13.1 Cadila Pharmaceuticals Company Information

7.13.2 Cadila Pharmaceuticals Introduction and Business Overview

7.13.3 Cadila Pharmaceuticals Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.13.4 Cadila Pharmaceuticals Broluzumab Biosimilars Product Offerings

7.13.5 Cadila Pharmaceuticals Recent Development

7.14 Dr Reddy's

7.14.1 Dr Reddy's Company Information

7.14.2 Dr Reddy's Introduction and Business Overview

7.14.3 Dr Reddy's Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.14.4 Dr Reddy's Broluzumab Biosimilars Product Offerings

7.14.5 Dr Reddy's Recent Development

7.15 Aurobindo Pharma

7.15.1 Aurobindo Pharma Company Information

7.15.2 Aurobindo Pharma Introduction and Business Overview

7.15.3 Aurobindo Pharma Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.15.4 Aurobindo Pharma Broluzumab Biosimilars Product Offerings

7.15.5 Aurobindo Pharma Recent Development

7.16 Biocad

7.16.1 Biocad Company Information

7.16.2 Biocad Introduction and Business Overview

7.16.3 Biocad Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.16.4 Biocad Broluzumab Biosimilars Product Offerings

7.16.5 Biocad Recent Development

7.17 MAbxience

7.17.1 MAbxience Company Information

7.17.2 MAbxience Introduction and Business Overview

7.17.3 MAbxience Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.17.4 MAbxience Broluzumab Biosimilars Product Offerings

7.17.5 MAbxience Recent Development

7.18 Hetero

7.18.1 Hetero Company Information

7.18.2 Hetero Introduction and Business Overview

7.18.3 Hetero Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.18.4 Hetero Broluzumab Biosimilars Product Offerings

7.18.5 Hetero Recent Development

7.19 Biocon

7.19.1 Biocon Company Information

7.19.2 Biocon Introduction and Business Overview

7.19.3 Biocon Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.19.4 Biocon Broluzumab Biosimilars Product Offerings

7.19.5 Biocon Recent Development

7.20 Kirin Biologics

7.20.1 Kirin Biologics Company Information

7.20.2 Kirin Biologics Introduction and Business Overview

7.20.3 Kirin Biologics Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.20.4 Kirin Biologics Broluzumab Biosimilars Product Offerings

7.20.5 Kirin Biologics Recent Development

7.21 Mylan

7.21.1 Mylan Company Information

7.21.2 Mylan Introduction and Business Overview

7.21.3 Mylan Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.21.4 Mylan Broluzumab Biosimilars Product Offerings

7.21.5 Mylan Recent Development

7.22 BeiGene

7.22.1 BeiGene Company Information

7.22.2 BeiGene Introduction and Business Overview

7.22.3 BeiGene Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.22.4 BeiGene Broluzumab Biosimilars Product Offerings

7.22.5 BeiGene Recent Development

7.23 Innovent

7.23.1 Innovent Company Information

7.23.2 Innovent Introduction and Business Overview

7.23.3 Innovent Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.23.4 Innovent Broluzumab Biosimilars Product Offerings

7.23.5 Innovent Recent Development

7.24 Qilu Pharmaceutical

7.24.1 Qilu Pharmaceutical Company Information

7.24.2 Qilu Pharmaceutical Introduction and Business Overview

7.24.3 Qilu Pharmaceutical Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.24.4 Qilu Pharmaceutical Broluzumab Biosimilars Product Offerings

7.24.5 Qilu Pharmaceutical Recent Development

7.25 Hengrui Pharmaceuticals

7.25.1 Hengrui Pharmaceuticals Company Information

7.25.2 Hengrui Pharmaceuticals Introduction and Business Overview

7.25.3 Hengrui Pharmaceuticals Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.25.4 Hengrui Pharmaceuticals Broluzumab Biosimilars Product Offerings

7.25.5 Hengrui Pharmaceuticals Recent Development

7.26 Hisun Pharmaceutical

7.26.1 Hisun Pharmaceutical Company Information

7.26.2 Hisun Pharmaceutical Introduction and Business Overview

7.26.3 Hisun Pharmaceutical Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.26.4 Hisun Pharmaceutical Broluzumab Biosimilars Product Offerings

7.26.5 Hisun Pharmaceutical Recent Development

7.27 TOT BIOPHARM

7.27.1 TOT BIOPHARM Company Information

7.27.2 TOT BIOPHARM Introduction and Business Overview

7.27.3 TOT BIOPHARM Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.27.4 TOT BIOPHARM Broluzumab Biosimilars Product Offerings

7.27.5 TOT BIOPHARM Recent Development

7.28 Luye Pharmaceutical

7.28.1 Luye Pharmaceutical Company Information

7.28.2 Luye Pharmaceutical Introduction and Business Overview

7.28.3 Luye Pharmaceutical Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.28.4 Luye Pharmaceutical Broluzumab Biosimilars Product Offerings

7.28.5 Luye Pharmaceutical Recent Development

7.29 Henlius

7.29.1 Henlius Company Information

7.29.2 Henlius Introduction and Business Overview

7.29.3 Henlius Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)

7.29.4 Henlius Broluzumab Biosimilars Product Offerings

7.29.5 Henlius Recent Development

8 Industry Chain Analysis

8.1 Broluzumab Biosimilars Industrial Chain

8.2 Broluzumab Biosimilars Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Broluzumab Biosimilars Sales Model

8.5.2 Sales Channel

8.5.3 Broluzumab Biosimilars Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Broluzumab Biosimilars Market Trends

Table 2. Broluzumab Biosimilars Market Drivers & Opportunity

Table 3. Broluzumab Biosimilars Market Challenges

Table 4. Broluzumab Biosimilars Market Restraints

Table 5. Global Broluzumab Biosimilars Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Broluzumab Biosimilars Revenue Market Share by Company (2020-2025)

Table 7. Global Broluzumab Biosimilars Sales Volume by Company (2020-2025) & (Units)

Table 8. Global Broluzumab Biosimilars Sales Volume Market Share by Company (2020-2025)

Table 9. Global Market Broluzumab Biosimilars Price by Company (2020-2025) & (K USD/Unit)

Table 10. Key Manufacturers Broluzumab Biosimilars Manufacturing Base and Headquarters

Table 11. Key Manufacturers Broluzumab Biosimilars Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Broluzumab Biosimilars

Table 13. Global Broluzumab Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Broluzumab Biosimilars as of 2024)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Broluzumab Biosimilars Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 17. Global Broluzumab Biosimilars Sales Value by Type (2020-2025) & (US$ Million)

Table 18. Global Broluzumab Biosimilars Sales Value by Type (2026-2031) & (US$ Million)

Table 19. Global Broluzumab Biosimilars Sales Market Share in Value by Type (2020-2025)

Table 20. Global Broluzumab Biosimilars Sales Market Share in Value by Type (2026-2031)

Table 21. Global Broluzumab Biosimilars Sales Volume by Type: 2020 VS 2024 VS 2031 (Units)

Table 22. Global Broluzumab Biosimilars Sales Volume by Type (2020-2025) & (Units)

Table 23. Global Broluzumab Biosimilars Sales Volume by Type (2026-2031) & (Units)

Table 24. Global Broluzumab Biosimilars Sales Market Share in Volume by Type (2020-2025)

Table 25. Global Broluzumab Biosimilars Sales Market Share in Volume by Type (2026-2031)

Table 26. Global Broluzumab Biosimilars Price by Type (2020-2025) & (K USD/Unit)

Table 27. Global Broluzumab Biosimilars Price by Type (2026-2031) & (K USD/Unit)

Table 28. Global Broluzumab Biosimilars Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 29. Global Broluzumab Biosimilars Sales Value by Application (2020-2025) & (US$ Million)

Table 30. Global Broluzumab Biosimilars Sales Value by Application (2026-2031) & (US$ Million)

Table 31. Global Broluzumab Biosimilars Sales Market Share in Value by Application (2020-2025)

Table 32. Global Broluzumab Biosimilars Sales Market Share in Value by Application (2026-2031)

Table 33. Global Broluzumab Biosimilars Sales Volume by Application: 2020 VS 2024 VS 2031 (Units)

Table 34. Global Broluzumab Biosimilars Sales Volume by Application (2020-2025) & (Units)

Table 35. Global Broluzumab Biosimilars Sales Volume by Application (2026-2031) & (Units)

Table 36. Global Broluzumab Biosimilars Sales Market Share in Volume by Application (2020-2025)

Table 37. Global Broluzumab Biosimilars Sales Market Share in Volume by Application (2026-2031)

Table 38. Global Broluzumab Biosimilars Price by Application (2020-2025) & (K USD/Unit)

Table 39. Global Broluzumab Biosimilars Price by Application (2026-2031) & (K USD/Unit)

Table 40. Global Broluzumab Biosimilars Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 41. Global Broluzumab Biosimilars Sales Value by Region (2020-2025) & (US$ Million)

Table 42. Global Broluzumab Biosimilars Sales Value by Region (2026-2031) & (US$ Million)

Table 43. Global Broluzumab Biosimilars Sales Value by Region (2020-2025) & (%)

Table 44. Global Broluzumab Biosimilars Sales Value by Region (2026-2031) & (%)

Table 45. Global Broluzumab Biosimilars Sales Volume by Region (Units): 2020 VS 2024 VS 2031

Table 46. Global Broluzumab Biosimilars Sales Volume by Region (2020-2025) & (Units)

Table 47. Global Broluzumab Biosimilars Sales Volume by Region (2026-2031) & (Units)

Table 48. Global Broluzumab Biosimilars Sales Volume by Region (2020-2025) & (%)

Table 49. Global Broluzumab Biosimilars Sales Volume by Region (2026-2031) & (%)

Table 50. Global Broluzumab Biosimilars Average Price by Region (2020-2025) & (K USD/Unit)

Table 51. Global Broluzumab Biosimilars Average Price by Region (2026-2031) & (K USD/Unit)

Table 52. Key Countries/Regions Broluzumab Biosimilars Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 53. Key Countries/Regions Broluzumab Biosimilars Sales Value, (2020-2025) & (US$ Million)

Table 54. Key Countries/Regions Broluzumab Biosimilars Sales Value, (2026-2031) & (US$ Million)

Table 55. Key Countries/Regions Broluzumab Biosimilars Sales Volume, (2020-2025) & (Units)

Table 56. Key Countries/Regions Broluzumab Biosimilars Sales Volume, (2026-2031) & (Units)

Table 57. Novartis Company Information

Table 58. Novartis Introduction and Business Overview

Table 59. Novartis Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 60. Novartis Broluzumab Biosimilars Product Offerings

Table 61. Novartis Recent Development

Table 62. Genentech Company Information

Table 63. Genentech Introduction and Business Overview

Table 64. Genentech Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 65. Genentech Broluzumab Biosimilars Product Offerings

Table 66. Genentech Recent Development

Table 67. Roche Company Information

Table 68. Roche Introduction and Business Overview

Table 69. Roche Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 70. Roche Broluzumab Biosimilars Product Offerings

Table 71. Roche Recent Development

Table 72. Pfizer Company Information

Table 73. Pfizer Introduction and Business Overview

Table 74. Pfizer Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 75. Pfizer Broluzumab Biosimilars Product Offerings

Table 76. Pfizer Recent Development

Table 77. Sartorius Company Information

Table 78. Sartorius Introduction and Business Overview

Table 79. Sartorius Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 80. Sartorius Broluzumab Biosimilars Product Offerings

Table 81. Sartorius Recent Development

Table 82. Eli Lilly Company Information

Table 83. Eli Lilly Introduction and Business Overview

Table 84. Eli Lilly Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 85. Eli Lilly Broluzumab Biosimilars Product Offerings

Table 86. Eli Lilly Recent Development

Table 87. Bayer Company Information

Table 88. Bayer Introduction and Business Overview

Table 89. Bayer Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 90. Bayer Broluzumab Biosimilars Product Offerings

Table 91. Bayer Recent Development

Table 92. Amgen Company Information

Table 93. Amgen Introduction and Business Overview

Table 94. Amgen Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 95. Amgen Broluzumab Biosimilars Product Offerings

Table 96. Amgen Recent Development

Table 97. PlantForm Company Information

Table 98. PlantForm Introduction and Business Overview

Table 99. PlantForm Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 100. PlantForm Broluzumab Biosimilars Product Offerings

Table 101. PlantForm Recent Development

Table 102. PharmaPraxis Company Information

Table 103. PharmaPraxis Introduction and Business Overview

Table 104. PharmaPraxis Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 105. PharmaPraxis Broluzumab Biosimilars Product Offerings

Table 106. PharmaPraxis Recent Development

Table 107. Samsung Bioepis Company Information

Table 108. Samsung Bioepis Introduction and Business Overview

Table 109. Samsung Bioepis Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 110. Samsung Bioepis Broluzumab Biosimilars Product Offerings

Table 111. Samsung Bioepis Recent Development

Table 112. Centus Company Information

Table 113. Centus Introduction and Business Overview

Table 114. Centus Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 115. Centus Broluzumab Biosimilars Product Offerings

Table 116. Centus Recent Development

Table 117. Cadila Pharmaceuticals Company Information

Table 118. Cadila Pharmaceuticals Introduction and Business Overview

Table 119. Cadila Pharmaceuticals Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 120. Cadila Pharmaceuticals Broluzumab Biosimilars Product Offerings

Table 121. Cadila Pharmaceuticals Recent Development

Table 122. Dr Reddy's Company Information

Table 123. Dr Reddy's Introduction and Business Overview

Table 124. Dr Reddy's Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 125. Dr Reddy's Broluzumab Biosimilars Product Offerings

Table 126. Dr Reddy's Recent Development

Table 127. Aurobindo Pharma Company Information

Table 128. Aurobindo Pharma Introduction and Business Overview

Table 129. Aurobindo Pharma Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 130. Aurobindo Pharma Broluzumab Biosimilars Product Offerings

Table 131. Aurobindo Pharma Recent Development

Table 132. Biocad Company Information

Table 133. Biocad Introduction and Business Overview

Table 134. Biocad Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 135. Biocad Broluzumab Biosimilars Product Offerings

Table 136. Biocad Recent Development

Table 137. MAbxience Company Information

Table 138. MAbxience Introduction and Business Overview

Table 139. MAbxience Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 140. MAbxience Broluzumab Biosimilars Product Offerings

Table 141. MAbxience Recent Development

Table 142. Hetero Company Information

Table 143. Hetero Introduction and Business Overview

Table 144. Hetero Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 145. Hetero Broluzumab Biosimilars Product Offerings

Table 146. Hetero Recent Development

Table 147. Biocon Company Information

Table 148. Biocon Introduction and Business Overview

Table 149. Biocon Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 150. Biocon Broluzumab Biosimilars Product Offerings

Table 151. Biocon Recent Development

Table 152. Kirin Biologics Company Information

Table 153. Kirin Biologics Introduction and Business Overview

Table 154. Kirin Biologics Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 155. Kirin Biologics Broluzumab Biosimilars Product Offerings

Table 156. Kirin Biologics Recent Development

Table 157. Mylan Company Information

Table 158. Mylan Introduction and Business Overview

Table 159. Mylan Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 160. Mylan Broluzumab Biosimilars Product Offerings

Table 161. Mylan Recent Development

Table 162. BeiGene Company Information

Table 163. BeiGene Introduction and Business Overview

Table 164. BeiGene Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 165. BeiGene Broluzumab Biosimilars Product Offerings

Table 166. BeiGene Recent Development

Table 167. Innovent Company Information

Table 168. Innovent Introduction and Business Overview

Table 169. Innovent Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 170. Innovent Broluzumab Biosimilars Product Offerings

Table 171. Innovent Recent Development

Table 172. Qilu Pharmaceutical Company Information

Table 173. Qilu Pharmaceutical Introduction and Business Overview

Table 174. Qilu Pharmaceutical Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 175. Qilu Pharmaceutical Broluzumab Biosimilars Product Offerings

Table 176. Qilu Pharmaceutical Recent Development

Table 177. Hengrui Pharmaceuticals Company Information

Table 178. Hengrui Pharmaceuticals Introduction and Business Overview

Table 179. Hengrui Pharmaceuticals Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 180. Hengrui Pharmaceuticals Broluzumab Biosimilars Product Offerings

Table 181. Hengrui Pharmaceuticals Recent Development

Table 182. Hisun Pharmaceutical Company Information

Table 183. Hisun Pharmaceutical Introduction and Business Overview

Table 184. Hisun Pharmaceutical Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 185. Hisun Pharmaceutical Broluzumab Biosimilars Product Offerings

Table 186. Hisun Pharmaceutical Recent Development

Table 187. TOT BIOPHARM Company Information

Table 188. TOT BIOPHARM Introduction and Business Overview

Table 189. TOT BIOPHARM Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 190. TOT BIOPHARM Broluzumab Biosimilars Product Offerings

Table 191. TOT BIOPHARM Recent Development

Table 192. Luye Pharmaceutical Company Information

Table 193. Luye Pharmaceutical Introduction and Business Overview

Table 194. Luye Pharmaceutical Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 195. Luye Pharmaceutical Broluzumab Biosimilars Product Offerings

Table 196. Luye Pharmaceutical Recent Development

Table 197. Henlius Company Information

Table 198. Henlius Introduction and Business Overview

Table 199. Henlius Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 200. Henlius Broluzumab Biosimilars Product Offerings

Table 201. Henlius Recent Development

Table 202. Key Raw Materials Lists

Table 203. Raw Materials Key Suppliers Lists

Table 204. Broluzumab Biosimilars Downstream Customers

Table 205. Broluzumab Biosimilars Distributors List

Table 206. Research Programs/Design for This Report

Table 207. Key Data Information from Secondary Sources

Table 208. Key Data Information from Primary Sources

List of Figures

Figure 1. Broluzumab Biosimilars Product Picture

Figure 2. Global Broluzumab Biosimilars Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Broluzumab Biosimilars Sales Value (2020-2031) & (US$ Million)

Figure 4. Global Broluzumab Biosimilars Sales Volume (2020-2031) & (Units)

Figure 5. Global Broluzumab Biosimilars Sales Price (2020-2031) & (K USD/Unit)

Figure 6. Broluzumab Biosimilars Report Years Considered

Figure 7. Global Broluzumab Biosimilars Players Revenue Ranking (2024) & (US$ Million)

Figure 8. Global Broluzumab Biosimilars Players Sales Volume Ranking (2024) & (Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Broluzumab Biosimilars Revenue in 2024

Figure 10. Broluzumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 11. Beovu Picture

Figure 12. Vsiqq Picture

Figure 13. Others Picture

Figure 14. Global Broluzumab Biosimilars Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 15. Global Broluzumab Biosimilars Sales Value Market Share by Type, 2024 & 2031

Figure 16. Global Broluzumab Biosimilars Sales Volume by Type (2020 VS 2024 VS 2031) & (Units)

Figure 17. Global Broluzumab Biosimilars Sales Volume Market Share by Type, 2024 & 2031

Figure 18. Global Broluzumab Biosimilars Price by Type (2020-2031) & (K USD/Unit)

Figure 19. Product Picture of ARMD

Figure 20. Product Picture of Kaposi Sarcoma

Figure 21. Product Picture of Glioblastoma

Figure 22. Global Broluzumab Biosimilars Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 23. Global Broluzumab Biosimilars Sales Value Market Share by Application, 2024 & 2031

Figure 24. Global Broluzumab Biosimilars Sales Volume by Application (2020 VS 2024 VS 2031) & (Units)

Figure 25. Global Broluzumab Biosimilars Sales Volume Market Share by Application, 2024 & 2031

Figure 26. Global Broluzumab Biosimilars Price by Application (2020-2031) & (K USD/Unit)

Figure 27. North America Broluzumab Biosimilars Sales Value (2020-2031) & (US$ Million)

Figure 28. North America Broluzumab Biosimilars Sales Value by Country (%), 2024 VS 2031

Figure 29. Europe Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 30. Europe Broluzumab Biosimilars Sales Value by Country (%), 2024 VS 2031

Figure 31. Asia Pacific Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Broluzumab Biosimilars Sales Value by Region (%), 2024 VS 2031

Figure 33. South America Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 34. South America Broluzumab Biosimilars Sales Value by Country (%), 2024 VS 2031

Figure 35. Middle East & Africa Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 36. Middle East & Africa Broluzumab Biosimilars Sales Value by Country (%), 2024 VS 2031

Figure 37. Key Countries/Regions Broluzumab Biosimilars Sales Value (%), (2020-2031)

Figure 38. Key Countries/Regions Broluzumab Biosimilars Sales Volume (%), (2020-2031)

Figure 39. United States Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 40. United States Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

Figure 41. United States Broluzumab Biosimilars Sales Value by Application (%), 2024 VS 2031

Figure 42. Europe Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 43. Europe Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

Figure 44. Europe Broluzumab Biosimilars Sales Value by Application (%), 2024 VS 2031

Figure 45. China Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 46. China Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

Figure 47. China Broluzumab Biosimilars Sales Value by Application (%), 2024 VS 2031

Figure 48. Japan Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 49. Japan Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

Figure 50. Japan Broluzumab Biosimilars Sales Value by Application (%), 2024 VS 2031

Figure 51. South Korea Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 52. South Korea Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

Figure 53. South Korea Broluzumab Biosimilars Sales Value by Application (%), 2024 VS 2031

Figure 54. Southeast Asia Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 55. Southeast Asia Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

Figure 56. Southeast Asia Broluzumab Biosimilars Sales Value by Application (%), 2024 VS 2031

Figure 57. India Broluzumab Biosimilars Sales Value, (2020-2031) & (US$ Million)

Figure 58. India Broluzumab Biosimilars Sales Value by Type (%), 2024 VS 2031

Figure 59. India Broluzumab Biosimilars Sales Value by Application (%), 2024 VS 2031

Figure 60. Broluzumab Biosimilars Industrial Chain

Figure 61. Broluzumab Biosimilars Manufacturing Cost Structure

Figure 62. Channels of Distribution (Direct Sales, and Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Broluzumab Biosimilars market? zhanKai

The top companies in the global Broluzumab Biosimilars market are Novartis、Genentech、Roche.

Related Reports

Global Broluzumab Biosimilars Market Research Report 2025
The global market for Broluzumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 119
USD 2900.00
(Single User License)
Global Broluzumab Biosimilars Market Research Report 2024
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published Date: 2024-01-20
Pages: 109
USD 2900.00
(Single User License)
Broluzumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published Date: 2024-01-11
Pages: 164
USD 3950.00
(Single User License)

Global Broluzumab Biosimilars Market Research Report 2025
The global market for Broluzumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 119
USD 2900.00 (Single User License)
Global Broluzumab Biosimilars Market Research Report 2024
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published: 2024-01-20
Pages: 109
USD 2900.00 (Single User License)
Broluzumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published: 2024-01-11
Pages: 164
USD 3950.00 (Single User License)